Iovance Biotherapeutics (IOVA) announced Health Canada has issued a notice of compliance with conditions for Amtagvi, a tumor-derived autologous T cell immunotherapy. Amtagvi is indicated for the treatment of adult patients with unresectable or metastatic melanoma that has progressed on or after at least one prior systemic therapy including a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor, and who have no satisfactory alternative treatment options.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics’ Earnings Call Highlights Growth
- Tesla disbands supercomputer team, Trade Desk Q2 spurs downgrades: Morning Buzz
- Iovance Biotherapeutics price target lowered to $14 from $18 at Wells Fargo
- Iovance Biotherapeutics Reports Strong Revenue Growth in Q2 2025
- Iovance Biotherapeutics: Overcoming Revenue Shortfalls with Strategic Growth Initiatives